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in Patients With Diabetes and
Multivessel Coronary Artery Disease
Has the Final Chapter Been Written?*Steven P. Marso, MD, Darren K. McGuire, MD, MHSCI n this issue of the Journal, Dangas et al. (1) reporton an important subgroup of patients from theFREEDOM (Comparison of Two Treatments for
Multivessel Coronary Artery Disease in Individuals
With Diabetes) trial, a trial in which patients with
type 2 diabetes mellitus (T2DM) and multivessel cor-
onary disease were randomized to revascularization
by percutaneous coronary intervention (PCI) usingSEE PAGE 1189drug-eluting stents versus coronary artery bypass
grafting (CABG) (2,3). The present analyses explore
the effectiveness of CABG versus PCI on the trial pri-
mary outcome among the 602 patients (32.5%) treated
with insulin (ITDM) at study entry (325 underwent
PCI; 277 underwent CABG), compared with the non–
insulin-treated subset (no ITDM).
Independent of revascularization assignment, in
the overall cohort, ITDM had higher risk for the pri-
mary composite outcome even after adjustment for
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Guest Editor for this paper.revascularization treatment (adjusted hazard ratio
[HR]: 1.35; 95% conﬁdence interval [CI]: 1.06 to 1.73).
Qualitatively consistent with the overall trial results,
in the ITDM subgroup, the primary event rate was
numerically higher with PCI versus CABG, although
not statistically signiﬁcant (HR: 1.21; 95% CI: 0.87 to
1.69). In this context, statistical testing for heteroge-
neity of treatment effect by insulin-treatment status
(i.e., testing for statistical interaction) yielded a
p value of >0.05. Thus, no statistically signiﬁcant
interaction by insulin treatment was evident. The
investigators concluded that in patients with T2DM
and multivessel coronary disease, insulin treatment
remains an independent marker of risk; and there
was no signiﬁcant difference in the magnitude of
the PCI versus the CABG treatment effect for T2DM
patients treated with or without insulin.
Estimating cardiovascular (CV) risk and the effec-
tiveness of CV therapies in T2DM patients is a moving
target, with continuous improvements in CV risk and
survival over recent decades (4). Yet, there remains an
unyielding “incremental risk” for patients with T2DM,
even after adjustment for CV risk factors commonly
concomitant with T2DM (4,5), with the adjusted risk
for major adverse CV events remaining 2- to 4-fold
greater in patients with T2DM. This reﬂects an impor-
tant gap in understanding the underpinnings of the
pathobiological nexus of T2DM and CV disease, and a
critically important unmet clinical need.
However, not all of the 29.1 million people with
T2DM in the United States have “coronary disease
equivalent” risk (4,6). Directly related to duration of
T2DM, CV risk increases over time, and quantifying
this risk may aid in medical decision making. In this
context, the presence of certain high-risk features
may inform clinicians on appropriate coronary
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Among others, age, duration of T2DM, insulin
treatment, and complexity of coronary disease are
oft-cited high-risk features. There are 2 equally plau-
sible hypotheses related to the treatment effect of
CABG relative to T2DM, multivessel disease, and high-
risk markers. The ﬁrst is that CABG versus PCI would
have greatest beneﬁt in T2DM patients with higher-
risk features, following the principal that the highest-
risk patients beneﬁt greatest from effective
therapies. An equally compelling hypothesis is that the
presence of T2DM requiring insulin treatment repre-
sents such a high-risk status in patients with multi-
vessel disease that the competing risk of comorbid
conditions could to some degree attenuate the beneﬁt
of CABG over PCI. Therefore, CABG versus PCI out-
comes could be more comparable in both absolute and
relative terms, independent of other proven prog-
nostic factors such as the SYNTAX score, age, or T2DM
duration. This is the crux of the importance of the
present analyses by Dangas et al. (1).
CONTEXT WITH PRIOR LITERATURE
It is important to place the results of the present
FREEDOM substudy into context with prior literature.
In general, recent trial data suggest concordance of
the beneﬁt of CABG versus PCI in patients with and
without T2DM who have multivessel coronary artery
disease. The 5-year results from the SYNTAX (Synergy
Between PCI With TAXUS and Cardiac Surgery) trial,
which randomized patients with multivessel coronary
disease to PCI versus CABG and included 296 patients
with T2DM, demonstrated that PCI was associated
with an increased HR of 2.3 for the composite of
death/myocardial infarction (MI)/cerebrovascular ac-
cident (CVA)/revascularization (7). Analyzing each
component, there was a 2-fold increase in mortality
(20.2% vs. 10.1%; p ¼ 0.027) and w3-fold increases in
MI (9.2% vs. 3.1%; p ¼ 0.056) and repeat revascular-
ization (33.2% vs. 12.5%; p < 0.001). Systematic re-
view of CABG versus PCI comparisons included 13
randomized controlled trials and 5 meta-analyses in
patients with T2DM and multivessel disease (8), and
suggests that CABG is preferred over PCI in appro-
priate patients with multivessel coronary disease and
T2DM. The authors further recommend that the
“guidelines be urgently updated to a class I, level A
indication.” However, this systematic review did not
explore heterogeneity of efﬁcacy of CABG versus PCI
by high-risk features. Whether the superiority of
CABG for patients with T2DM and multivessel disease
is independent of T2DM treatment regimens and
disease complexity is less clear from the availableliterature. Both the SYNTAX and FREEDOM inves-
tigators have explored these associations by com-
paring outcomes stratiﬁed by insulin treatment, and
using the SYNTAX score as a surrogate for coronary
disease complexity.
SYNTAX SCORE
Results from the FREEDOM and SYNTAX trials suggest
greater treatment beneﬁt of CABG versus PCI with
increasing complexity of coronary artery disease (3).
In the original FREEDOM report, the HR was numeri-
cally lower in the patients with a SYNTAX score of
#22 versus a score of >22 (1.14 vs. 1.46). The trend was
also seen in the present analyses by Dangas et al. (1).
Among the non-ITDM patients, the HRs were 1.18,
1.61, and 1.58 favoring CABG with increasing SYNTAX
scores of #22, 23 to 32, and $33, respectively. For pa-
tients with ITDM, the HRs were 0.84 (favoring PCI),
1.56, and 1.27 (favoring CABG) with SYNTAX scores
of #22, 23 to 32, and $33, respectively. A similar nu-
merical trend was seen in the 3-year results of the
SYNTAX diabetes mellitus (DM) substudy (9). In fact,
the point estimate favored PCI in DM patients with
SYNTAX scores of <22 in those analyses.
INSULIN TREATMENT
Subgroup analyses of DM patients stratiﬁed by insulin
treatment have been reported from the SYNTAX trial
(9), and now by Dangas et al. (1) from the FREEDOM
trial. The substudies from these 2 large-scale, ran-
domized trials are discordant. The SYNTAX analyses
suggest a greater magnitude of treatment beneﬁt of
CABG versus PCI in the ITDM group, whereas the
FREEDOM analyses suggest a numerically decreased
effect size. In SYNTAX, there were 182 patients with
T2DM treated with insulin and 270 treated with oral
agents (9). For patients treated with oral agents, there
was an increased estimate of risk for the composite of
death/MI/CVA in those randomized to CABG versus
PCI (12.0% vs. 7.2%; risk ratio [RR]: 0.6; p ¼ 0.19), and
a decreased risk estimate in those treated with insulin
(8.0% vs. 14.8%; RR: 1.84; p ¼ 0.16), though neither
analysis achieved statistical difference. The insulin
status-by-treatment group interaction term in the
SYNTAX analyses was p ¼ 0.06. In the FREEDOM
substudy, the treatment beneﬁt of CABG versus PCI
for the composite of death/MI/CVA was statistically
signiﬁcant in the subgroup of patients treated with
oral agents (15.6% vs. 23.2%; RR: 1.46) with qualita-
tively similar trends observed in the ITDM group
(24.3% vs. 32.2%), though analysis of this latter sub-
group did not achieve statistical difference (HR: 1.21;
95% CI: 0.87 to 1.69). Notably, in contrast with the
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lower in the ITDM group, noting that the insulin
status-by-treatment group interaction in the
FREEDOM analyses was not signiﬁcant (pinteraction ¼
0.40), statistically excluding heterogeneity of treat-
ment efﬁcacy by insulin treatment status.
The authors’ conclusion that CABG is superior to PCI
in “both groups” is not supported by their stratiﬁed
analyses, given the absence of statistical difference in
the ITDM subset, though the results observed in the
groups stratiﬁed by insulin treatment were qualita-
tively similar (unlike the SYNTAX ITDM vs. no ITDM
comparison). Similarly challenging is the authors’
interpretation of the statistically negative interaction
term to demonstrate “similarity.” As opposed to
concluding similarity, on the basis of present results,
one can only conclude that there is no statistical evi-
dence of heterogeneity of treatment effect, as these
analyses are extremely underpowered to rigorously
evaluate for interaction. In that light, excepting the
rare case of formal statistical testing for equivalence
(10), interpretation of comparisons failing to achieve
nominal statistical signiﬁcance should be limited to
concluding that no statistical difference is observed,
and not that the comparator groups are similar. Thus,
in the present study, similarity has not been estab-
lished by the negative interaction testing, and espe-
cially notable is the more than 2-fold differential in the
adjusted point estimates of treatment effect—risk dif-
ferences favoring CABG of 21% in the ITDM contrasted
with 46% in the no ITDM group.
Both the SYNTAX and FREEDOM ITDM analyses
are limited given the subgroup nature of the analyses
and lack of statistical power, both for between-group
comparisons within the strata and for interaction
testing across the strata. For example, to detect the
PCI versus CABG HRs of 1.2 observed in the ITDM
subgroup, with 85% power and 2-sided alpha ¼ 0.05,
there would need to be approximately 1,200 patients
in that subgroup (i.e., double the size of the ITDM
cohort in the FREEDOM trial). Given that the con-
ﬂicting results of these 2 substudies from the SYNTAX
and FREEDOM trials cannot both be accurate, the
differences must be attributed to either chance orbias. Without additional trials speciﬁcally designed to
test the hypothesis of heterogeneity of treatment
effects of CABG versus PCI by insulin treatment sta-
tus, it is not possible to resolve the “truth” from the
current data. In such a case, the most logical inter-
pretation of the aggregate data is that in the absence
of compelling information otherwise, the subsets of
patients stratiﬁed by insulin use should be expected
to derive treatment beneﬁts most comparable to
those observed in the overall trial.
PAST IS PROLOGUE
With the advent of novel therapies to manage T2DM
and CV risk, it has been the longstanding goal to in-
crease the number of patients who can be effectively
managed with optimal medical therapy and modern
PCI approaches, rather than with CABG. Data from the
FREEDOM and SYNTAX trials (8), and a recent sys-
tematic review suggest that we are no closer to real-
izing this goal in 2014 than we were following the 1995
National Heart Lung and Blood Institute BARI Clinical
Alert (11). Short of the introduction of new disruptive
CABG or PCI therapies, additional trials are not likely
to better inform physicians until clinicians and basic
scientists can better characterize the phenotype of
T2DM and CV risk. The key to closing the gap between
themeasured efﬁcacy of CABG and PCI will not be with
the advent of the “next-generation drug-eluting
stent” or even with the introduction of the bio-
resorbable stent, but rather with the ability to better
discern risk in patients with T2DM and with the
development of novel medical therapies to mitigate
disease progression and the future risk of nonfatal MI.
Only then will PCI have a ﬁghting chance of being an
effective treatment in patients with T2DM and
markers of high risk.
REPRINT REQUEST AND CORRESPONDENCE: Dr.
Steven P. Marso, University of Texas Southwestern,
Department of Internal Medicine, Professional Ofﬁce
Building Ofﬁce 1, Suite 8.110, 5959 Harry Hines
Boulevard, Dallas, Texas 75390-9047. E-mail: Steven.
Marso@UTSouthwestern.edu.RE F E RENCE S1. Dangas GD, Farkouh ME, Sleeper LA, et al.
Long-term outcome of PCI versus CABG in insulin
and non–insulin-treated diabetic patients: results
from the FREEDOM trial. J Am Coll Cardiol 2014;
64:1189–97.
2. Farkouh ME, Dangas G, Leon MB, et al.
Design of the Future REvascularization Evaluation
in patients with Diabetes mellitus: Optimalmanagement of Multivessel disease (FREEDOM)
trial. Am Heart J 2008;155:215–23.
3. Farkouh ME, Domanski M, Sleeper LA, et al.
Strategies for multivessel revascularization in
patients with diabetes. N Engl J Med 2012;367:
2375–84.
4. Go AS, Mozaffarian D, Roger VL, et al. Heart
disease and stroke statistics—2014 update: areport from the American Heart Association.
Circulation 2014;129:e28–292.
5. Gregg EW, Li Y, Wang J, et al. Changes in
diabetes-related complications in the United States,
1990-2010. N Engl J Med 2014;370:1514–23.
6. Centers for Disease Control and Prevention.
National Diabetes Statistical Report: Estimates of
Diabetes and Its Burdens in the United States,
J A C C V O L . 6 4 , N O . 1 2 , 2 0 1 4 Marso and McGuire
S E P T E M B E R 2 3 , 2 0 1 4 : 1 1 9 8 – 2 0 1 Coronary Revascularization in Diabetes
12012014. Atlanta, GA: US Department of Health and
Human Services, 2014.
7. Mohr FW, Morice MC, Kappetein AP, et al.
Coronary artery bypass graft surgery versus per-
cutaneous coronary intervention in patients with
three-vessel disease and left main coronary dis-
ease: 5-year follow-up of the randomised, clinical
SYNTAX trial. Lancet 2013;381:629–38.
8. Deb S, Wijeysundera HC, Ko DT, Tsubota H,
Hill S, Fremes SE. Coronary artery bypass graft
surgery vs percutaneous interventions in coronaryrevascularization: a systematic review. JAMA
2013;310:2086–95.
9. BanningAP,WestabyS,MoriceMC, et al. Diabetic
and nondiabetic patients with left main and/or
3-vessel coronary artery disease: comparison of
outcomes with cardiac surgery and paclitaxel-
eluting stents. J Am Coll Cardiol 2010;55:1067–75.
10. Assessment of the Safety and Efﬁcacy of
a New Thrombolytic (ASSENT-2) Investigators,
Van De Werf F, Adgey J, et al. Single-bolus ten-
ecteplase compared with front-loaded alteplase inacute myocardial infarction: the ASSENT-2 double-
blind randomised trial. Lancet 1999;354:716–22.
11. National Heart Lung and Blood Institute. BARI
Clinical Alert: Bypass Over Angioplasty for
Patients With Diabetes. National Institutes of
Health. September 21, 1995. Available at: http://
www.nlm.nih.gov/databases/alerts/bypass_diabetes.
html. Accessed July 15, 2014.
KEY WORDS CABG, diabetes mellitus, PCI,
revascularization
